Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder. It also develops NMRA-511 that is in phase 1 clinical trials in patients with agitation associated with dementia due to Alzheimer's disease; and NMRA-266, which is in the phase 1 clinical trial for the treatment of schizophrenia and other neuropsychiatric disorders. In addition, its preclinical phase product includes NMRA-NMDA for the treatment of schizophrenia; NMRA-CK1d, a CK1d inhibitor program for the treatment of amyotrophic lateral sclerosis; NMRA-NLRP3 for the treatment of certain neurodegenerative conditions; and NMRA-GCase for the treatment of Parkinson's disease. The company was formerly known as RBNC Therapeutics, Inc. and changed its name to Neumora Therapeutics, Inc. in October 2021. Neumora Therapeutics, Inc. was incorporated in 2019 and is headquartered in Watertown, Massachusetts.

Neumora Therapeutics, Inc. Common Stock

Brain diseases collectively represent one of the largest areas of unmet medical need, affecting upwards of 1.5 billion patients globally. Neumora was founded to confront the global brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. Our goal is to redefine neuroscience drug development by bringing forward the next generation of novel therapies that offer improved treatment outcomes and quality of life for patients.

We’ve built a pipeline comprised of programs for neuropsychiatric disorders and neurodegenerative diseases, each targeting a novel mechanism of action where we can leverage our precision neuroscience approach. Our pipeline currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. 

Neumora is committed to addressing some of the most prevalent brain health disorders and transforming the standard of care for millions of patients living with brain diseases. Learn more about Neumora and career opportunities on our website below.

Mubadala Capital Ventures

Invus

Abu Dhabi Growth Fund

Altitude Life Science Ventures

Amgen

EXOR N.V.

ARCH Venture Partners

Newpath Management

Polaris Partners

F-Prime Capital

Neumora

We are delighted to welcome Kaya Pai Panandiker as Chief Commercial Officer. Kaya brings to Neumora extensive commercial strategy and execution expertise, having led the launches of multiple neuropsychiatry products throughout her career. Read more: https://lnkd.in/ex-Zr2JP

Each year, our CEO Excellence Awards celebrate individuals or cross functional teams who demonstrate our values every day by achieving the extraordinary, creating value and doing what is right. We were thrilled to recognize our 2023 winners, Karla Zeitz, Jason Morton, Partha Mudipalli, Ph.D., Hong Ji, Santnu P., Michael Eyre, Heather Stemper, Palwasha T., Leanna Bui, Tash Barrow, Kelly Voong and Anh Le Vynh, for their outstanding contributions to Neumora. Thank you for your unwavering dedication to this work!

We’ve had a great week connecting with #JPM24 attendees! #ICYMI, check out CEO Henry Gosebruch’s podium presentation, outlining the exciting year ahead and our industry-leading pipeline. We look forward to continuing to pioneer a new era in brain disease and lead innovation in brain health throughout 2024. https://lnkd.in/eRFzBnEY

Neumora was founded to improve the lives of people living with brain diseases. To do that, we’ve built an industry-leading pipeline comprised of programs for neuropsychiatric disorders and neurodegenerative diseases, each targeting a novel mechanism of action. Learn more about our pipeline below. #JPM24

We are heading to San Francisco next week for #JPM24! CEO Henry Gosebruch will present on Monday, January 8 at 11:15AM PT. Learn more below. https://lnkd.in/ePiU73Zx

We are headed into this holiday season filled with gratitude for those around us. Wishing you the happiest of holidays from all of us at Neumora!

A recent NAMI study found that 64% of people with a mental illness said holidays make their conditions worse. It's important to put yourself first and prioritize your well-being, especially during the holiday season. We're sharing some of our favorite tips from NAMI and The Jed Foundation (JED) on how to reduce stress and maintain good #mentalhealth in the coming weeks. In an emergency, dial 988 to reach the suicide and crisis lifeline.

We are pleased to welcome Jason G. Duncan to Neumora as Chief Legal Officer. Jason's decades of legal, compliance, development and operations experience will be invaluable to our team as we continue to progress our pipeline. Read more: https://lnkd.in/eUdk_Gkr

We had a great time in Tampa at #ACNP2023, where Dr. Sanjay Mathew presented data from our #MDD program. It was great to connect with so many neuropsych thought leaders!

Today we announced IND clearance and the initiation of a Phase 1 study for NMRA-266, our M4 positive allosteric modulator. Read more here. https://lnkd.in/e_Vz_cjb

	Dec '20	Dec '21	Dec '22	Dec '23
net income	-99.27M -	-237.31M 139.05%	-130.90M 44.84%	-235.93M 80.23%
depreciation and amortization	105K -	538K 412.38%	594K 10.41%	668K 12.46%
deferred income tax	3.08M -	-53K 101.72%	-1.28M 2,324.53%	-3.74M 191.13%
stock based compensation	1.68M -	4.27M 155.16%	8.30M 94.15%	17.24M 107.76%
change in working capital	-3.12M -	-961K 69.24%	-6.95M 623.00%	-8.90M 28.08%
accounts receivables
inventory
accounts payables	-4.67M -	-759K 83.76%	-1.25M 64.16%	-581K 53.37%
other working capital	1.55M -	-202K 113.04%	-5.70M 2,722.77%	-8.32M 45.88%
other non cash items	70.77M -	158.09M 123.38%	15.35M 90.29%	67.38M 338.98%
net cash provided by operating activities	-26.76M -	-75.42M 181.84%	-114.90M 52.34%	-163.28M 42.11%
investments in property plant and equipment	-1.30M -	-817K 37.15%	-511K 37.45%	-117K 77.10%
acquisitions net
purchases of investments			-226.37M -	-109.07M 51.82%
sales maturities of investments			71.87M -	178.17M 147.91%
other investing activites	-9.94M -		-13M -	-4.59M 64.69%
net cash used for investing activites	-11.24M -	-817K 92.73%	-168.01M 20,464.63%	64.39M 138.32%
debt repayment
common stock issued	3.19M -	960K 69.91%		233.38M -
common stock repurchased	-2K -			-491K -
dividends paid
other financing activites	226.91M -	292.55M 28.93%	115.74M 60.44%	-948K 100.82%
net cash used provided by financing activities	230.10M -	293.51M 27.56%	115.74M 60.57%	231.94M 100.39%
effect of forex changes on cash
net change in cash	192.10M -	217.27M 13.10%	-167.17M 176.94%	133.04M 179.59%
cash at beginning of period		192.10M -	409.37M 113.10%	242.21M 40.83%
cash at end of period	192.10M -	409.37M 113.10%	242.21M 40.83%	375.25M 54.93%
operating cash flow	-26.76M -	-75.42M 181.84%	-114.90M 52.34%	-163.28M 42.11%
capital expenditure	-1.30M -	-817K 37.15%	-511K 37.45%	-117K 77.10%
free cash flow	-28.06M -	-76.24M 171.69%	-115.41M 51.38%	-163.40M 41.58%

COM:NEUMORATX

Neumora Therapeutics, Inc.

Last Close

9.69

22/11 21:00

Market Cap

1.72B

Beta: -

Volume Today

490.17K

Avg: -

Preview